WO2005009971A1 - キノロン誘導体又はその塩 - Google Patents
キノロン誘導体又はその塩 Download PDFInfo
- Publication number
- WO2005009971A1 WO2005009971A1 PCT/JP2004/010781 JP2004010781W WO2005009971A1 WO 2005009971 A1 WO2005009971 A1 WO 2005009971A1 JP 2004010781 W JP2004010781 W JP 2004010781W WO 2005009971 A1 WO2005009971 A1 WO 2005009971A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- compound
- amino
- oxo
- ethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 40
- 150000007660 quinolones Chemical class 0.000 title claims abstract description 17
- 229940127218 antiplatelet drug Drugs 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims abstract description 24
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims abstract description 20
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 292
- -1 cyclohexylamino Chemical group 0.000 claims description 167
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 94
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 239000002172 P2Y12 inhibitor Substances 0.000 claims description 17
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- OZJHCTLVCWYEKU-UHFFFAOYSA-N [2-[[7-(cyclohexylamino)-6-fluoro-4-oxo-1-pentan-3-ylquinoline-3-carbonyl]amino]-1,1-difluoroethyl]phosphonic acid Chemical compound C1=C2N(C(CC)CC)C=C(C(=O)NCC(F)(F)P(O)(O)=O)C(=O)C2=CC(F)=C1NC1CCCCC1 OZJHCTLVCWYEKU-UHFFFAOYSA-N 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 229960005137 succinic acid Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 120
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 65
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- 238000000034 method Methods 0.000 description 62
- 239000000243 solution Substances 0.000 description 61
- 238000001816 cooling Methods 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 230000002829 reductive effect Effects 0.000 description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 238000004519 manufacturing process Methods 0.000 description 42
- 238000003756 stirring Methods 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- 230000008569 process Effects 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000002904 solvent Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 239000002994 raw material Substances 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 235000011054 acetic acid Nutrition 0.000 description 17
- 238000010438 heat treatment Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 16
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 16
- 239000012312 sodium hydride Substances 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 150000002170 ethers Chemical class 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 150000008282 halocarbons Chemical class 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 10
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 150000007530 organic bases Chemical class 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 101710192338 P2Y purinoceptor 12 Proteins 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 7
- 238000007363 ring formation reaction Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000006482 condensation reaction Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 6
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 235000011941 Tilia x europaea Nutrition 0.000 description 5
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 5
- 239000004571 lime Substances 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000003332 Ilex aquifolium Nutrition 0.000 description 4
- 241000209027 Ilex aquifolium Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 206010038563 Reocclusion Diseases 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000002862 amidating effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- VTIJFLNLHCYVPF-UHFFFAOYSA-N C[SiH](C)C.Br Chemical compound C[SiH](C)C.Br VTIJFLNLHCYVPF-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000007259 addition reaction Methods 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- RAYMXZBXQCGRGX-UHFFFAOYSA-N quinoline-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-N 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine Chemical compound ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 2
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 2
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 2
- DJXNJVFEFSWHLY-UHFFFAOYSA-M quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-M 0.000 description 2
- VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- YQFFHPXGRDVLLR-UHFFFAOYSA-N (2,3,4-triphenylphenyl)phosphane Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC=CC=2)C(P)=CC=C1C1=CC=CC=C1 YQFFHPXGRDVLLR-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NGOTYFZFWPHNSU-UHFFFAOYSA-N 1,3-dioxol-4-amine Chemical compound NC1=COCO1 NGOTYFZFWPHNSU-UHFFFAOYSA-N 0.000 description 1
- DTYLXDLAOLOTKT-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=C1 DTYLXDLAOLOTKT-UHFFFAOYSA-N 0.000 description 1
- CGXLVFZJJOXEDF-UHFFFAOYSA-N 1,8-naphthyridine-3-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CN=C21 CGXLVFZJJOXEDF-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- VJZKRCMMKBITFO-UHFFFAOYSA-N 1-methylidene-2h-pyridin-1-ium Chemical compound C=[N+]1CC=CC=C1 VJZKRCMMKBITFO-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- STBGCAUUOPNJBH-UHFFFAOYSA-N 2,4,5-trifluorobenzoyl chloride Chemical compound FC1=CC(F)=C(C(Cl)=O)C=C1F STBGCAUUOPNJBH-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- VMKBHEMLMOAZMJ-UHFFFAOYSA-N 2-[7-(cyclohexylamino)-3-ethoxycarbonyl-6-fluoro-4-oxoquinolin-1-yl]propanoic acid Chemical compound FC=1C=C2C(=O)C(C(=O)OCC)=CN(C(C)C(O)=O)C2=CC=1NC1CCCCC1 VMKBHEMLMOAZMJ-UHFFFAOYSA-N 0.000 description 1
- IDIWLOODSHDOPG-HNNXBMFYSA-N 2-[[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-oxolan-3-yl]quinoline-3-carbonyl]amino]ethylphosphonic acid Chemical compound C12=CC(NC3CCCCC3)=C(F)C=C2C(=O)C(C(=O)NCCP(O)(=O)O)=CN1[C@H]1CCOC1 IDIWLOODSHDOPG-HNNXBMFYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
- DERAACKMMNJAFU-UHFFFAOYSA-N 2-ethoxy-1,3-dioxane-4,6-dione Chemical compound CCOC1OC(=O)CC(=O)O1 DERAACKMMNJAFU-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CLHIEFRGURJBOM-UHFFFAOYSA-N 3,4,5-trifluoro-n-pentan-3-ylaniline Chemical compound CCC(CC)NC1=CC(F)=C(F)C(F)=C1 CLHIEFRGURJBOM-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- ONELILMJNOWXSA-UHFFFAOYSA-N 3-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(Br)=C1 ONELILMJNOWXSA-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZIPLRYYWAXPVMG-UHFFFAOYSA-N 4-oxo-1h-cinnoline-3-carboxylic acid Chemical compound C1=CC=C2C(=O)C(C(=O)O)=NNC2=C1 ZIPLRYYWAXPVMG-UHFFFAOYSA-N 0.000 description 1
- CVAWACBLSANHSQ-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=CC=CC2=C(O)C(C(=O)N)=CN=C21 CVAWACBLSANHSQ-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- QYGNDKJRRNVSEC-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-pyrrole Chemical compound COC1=NCCC1 QYGNDKJRRNVSEC-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- AURKWGDNLYYPEQ-UHFFFAOYSA-N 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-2-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(C3CCCC3)C(C)=C(C(O)=O)C(=O)C2=CC(F)=C1NC1CCCCC1 AURKWGDNLYYPEQ-UHFFFAOYSA-N 0.000 description 1
- JVCAPXIILZCWTB-UHFFFAOYSA-N 7-(cyclohexylamino)-6-fluoro-1-(1-hydroxypropan-2-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound CC(CO)N1C=C(C(=O)C2=CC(=C(C=C21)NC3CCCCC3)F)C(=O)O JVCAPXIILZCWTB-UHFFFAOYSA-N 0.000 description 1
- QPWNYRZIZQHSIC-UHFFFAOYSA-N 9-(cyclohexylamino)-8-fluoro-6-oxo-1,2,3,4-tetrahydrobenzo[c]quinolizine-5-carboxylic acid Chemical compound FC=1C=C2C(=O)C(C(=O)O)=C3CCCCN3C2=CC=1NC1CCCCC1 QPWNYRZIZQHSIC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JWQNMZVYTPNHKI-UHFFFAOYSA-N Br.P(O)(O)=O Chemical compound Br.P(O)(O)=O JWQNMZVYTPNHKI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PSCXEUSWZWRCMQ-UHFFFAOYSA-N F[S](F)F Chemical compound F[S](F)F PSCXEUSWZWRCMQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FYCMHMJZICUJHW-UHFFFAOYSA-N N#CC(CC1=CC=CC=C1)OP(O)=O Chemical compound N#CC(CC1=CC=CC=C1)OP(O)=O FYCMHMJZICUJHW-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- QNAMPIYNAKZESU-UHFFFAOYSA-N OP(OCC1NCCCC1)=O Chemical compound OP(OCC1NCCCC1)=O QNAMPIYNAKZESU-UHFFFAOYSA-N 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- PAAZCQANMCYGAW-UHFFFAOYSA-N acetic acid;2,2,2-trifluoroacetic acid Chemical compound CC(O)=O.OC(=O)C(F)(F)F PAAZCQANMCYGAW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- GRKUXCWELVWVMZ-UHFFFAOYSA-N amino acetate Chemical compound CC(=O)ON GRKUXCWELVWVMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- CAMXVZOXBADHNJ-UHFFFAOYSA-N ammonium nitrite Chemical compound [NH4+].[O-]N=O CAMXVZOXBADHNJ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- GHNBEBDYYSVNEK-UHFFFAOYSA-N capillon Natural products CC=CC=CC(=O)C1=CC=CC=C1 GHNBEBDYYSVNEK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- OEVBBHLHYFALIW-UHFFFAOYSA-N cinnoline-3-carbonitrile Chemical compound C1=CC=C2N=NC(C#N)=CC2=C1 OEVBBHLHYFALIW-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- ZCXIFQYOEZLHSP-UHFFFAOYSA-N dicyanophosphorylformonitrile Chemical compound N#CP(=O)(C#N)C#N ZCXIFQYOEZLHSP-UHFFFAOYSA-N 0.000 description 1
- MOXXPQWMYMUHHV-UHFFFAOYSA-N diethoxymethanol Chemical compound CCOC(O)OCC MOXXPQWMYMUHHV-UHFFFAOYSA-N 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QMQGGCRCCRHQNF-UHFFFAOYSA-N ethyl 3-(2-chloro-4,5-difluorophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC(F)=C(F)C=C1Cl QMQGGCRCCRHQNF-UHFFFAOYSA-N 0.000 description 1
- YOJMIDBWSLQVER-UHFFFAOYSA-N ethyl 3-(cyclopentylamino)-2-(2,4,5-trifluorobenzoyl)but-2-enoate Chemical compound C=1C(F)=C(F)C=C(F)C=1C(=O)C(C(=O)OCC)=C(C)NC1CCCC1 YOJMIDBWSLQVER-UHFFFAOYSA-N 0.000 description 1
- PJQSOYUPQJJGOK-UHFFFAOYSA-N ethyl 5,6,7-trifluoro-4-oxo-1-pentan-3-ylquinoline-3-carboxylate Chemical compound FC1=C(F)C(F)=C2C(=O)C(C(=O)OCC)=CN(C(CC)CC)C2=C1 PJQSOYUPQJJGOK-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003849 fibrinolytic balance Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 150000004050 homopiperazines Chemical class 0.000 description 1
- 102000043971 human P2RY12 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- MHOVLDXJDIEEMJ-UHFFFAOYSA-N oxolan-3-amine;hydrochloride Chemical compound Cl.NC1CCOC1 MHOVLDXJDIEEMJ-UHFFFAOYSA-N 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- MNQZHTRAKIMKJF-UHFFFAOYSA-N piperidin-3-ylphosphonic acid Chemical compound OP(O)(=O)C1CCCNC1 MNQZHTRAKIMKJF-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- RDZVYRXKJFCUMP-UHFFFAOYSA-N pyridin-3-yl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=CN=C1 RDZVYRXKJFCUMP-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- RAYMXZBXQCGRGX-UHFFFAOYSA-M quinoline-5-carboxylate Chemical compound C1=CC=C2C(C(=O)[O-])=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-M 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- RHUVFRWZKMEWNS-UHFFFAOYSA-M silver thiocyanate Chemical compound [Ag+].[S-]C#N RHUVFRWZKMEWNS-UHFFFAOYSA-M 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Definitions
- the present invention provides a platelet aggregation inhibitor and a P2Y12 inhibitor containing a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a medicament, particularly a platelet aggregation inhibitor, which is useful as a P2Y12 inhibitor.
- the present invention relates to a novel quinopene derivative or a pharmaceutically acceptable salt thereof. Background art.
- Platelets have long been treated as a component of blood needed for hemostasis since its discovery by Donne in 1842.
- Today, platelets not only play a leading role in the hemostatic mechanism but also establish atherosclerosis, which is of clinical interest, circulatory diseases including thrombotic diseases, cancer metastasis, inflammation, rejection after transplantation, and immunity It has been shown to exhibit multiple functions, such as involvement in reactions. ''
- Non-Patent Document 1 Treatment for thrombotic and ischemic diseases is used to restore blood circulation by drugs or physical methods. Recently, platelet activation, adhesion, and coagulation due to disruption of vascular tissue, including endothelial cells, or disruption of fibrinolysis / coagulation balance due to the drug itself, following recent revascularization. has been found to be a clinical problem. For example, after re-communication was obtained by thrombolytic therapy using t-PA etc., it was revealed that fibrinolytic and coagulant activities were activated, and systemic coagulation 'fibrinolytic balance collapsed. . Implantation causes reocclusion and is a major therapeutic problem (Non-Patent Document 1).
- PTCA therapy-stenting has rapidly spread to the treatment of diseases based on coronary stenosis and aortic stenosis such as angina pectoris and myocardial infarction, and has achieved certain results.
- these therapies damage vascular tissues, including endothelial cells, causing acute coronary obstruction and restenosis during the chronic phase.
- Various thrombotic adverse effects (reocclusion, etc.) following such revascularization therapy The board plays an important role. Therefore, the efficacy of antiplatelet agents is expected to be sufficient. Conventional antiplatelet agents have not yet proved to be sufficiently effective.
- Non-Patent Document 1 Journal of the American College of Cardiology (Journal of the American College of Cardiology), 1988, Vol. 12, .616-623
- Non-patent Document 2 Clinical, 2003, Vol. 52, p. 1516-1521
- Patent Document 1 International Publication No. WO 00/34283 Pamphlet
- Patent Document 2 International Publication No. W0 02/098856 Pamphlet
- Patent Document 3 International Publication No. W003 / 022214 pamphlet
- Patent Document 4 International Publication No. WO 98/23592 Pamphlet Disclosure of the Invention
- the present invention provides a platelet aggregation inhibitor and a P2Y12 inhibitor, which have high pharmacological effects and are used for balancing pharmacological effects and safety, and provide a high pharmacological effect and a balance between pharmacological effects and safety.
- An object of the present invention is to provide a novel compound which is excellent as a platelet aggregation inhibitor and a P2Y12 inhibitor.
- the present invention relates to a platelet aggregation inhibitor containing, as an active ingredient, a quinolone derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof.
- X CR 7 or N.
- R u —H, an optionally substituted lower alkyl, or an amino which may be substituted with an optionally substituted lower alkyl.
- R 12 —H, or lower alkyl or aryl, each of which may be substituted.
- R 11 and R 12 may be combined with an adjacent nitrogen atom to form an optionally substituted cyclic amino.
- R 2 optionally substituted lower alkyl, cycloalkyl, aryl Or a heterocycle.
- R 3 halogen, lower alkyl, or —0-lower alkyl.
- R 4 Cycloalkyl or non-aromatic heterosulf, which may be substituted, or lower alkyl substituted with cycloalkyl. However, when R 4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring is bonded to an adjacent NH.
- R 5 -H, halogen, cyano, nitro, lower alkyl, halogeno lower alkyl, cycloalkyl, aryl, heterocycle, -0-lower alkyl, -OH, -NHCO-lower alkyl, -N (lower alkyl) CO-amino which may be substituted with lower alkyl, lower alkyl, or cyclic amino which may be substituted. .
- R 6 —H, halogen, lower alkyl or halogeno lower alkyl.
- R 7 -H, halogen, lower alkyl or halogeno-lower alkyl.
- R 2 and R 6 may be combined to form lower alkylene or lower alkylene.
- a P2Y12 inhibitor comprising, as an active ingredient, the quinolone derivative of the above formula (I) or a pharmaceutically acceptable salt thereof.
- X CR 7 or N.
- R 11 —H, optionally substituted lower alkyl, or optionally substituted lower alkyl, amino.
- R 12 - ⁇ , or each may be substituted! /, Lower alkyl or aryl. 'However, R 11 and R 12 may be combined with an adjacent nitrogen atom to form an optionally substituted cyclic amino. .
- R 2 optionally substituted, lower alkyl, cycloalkyl, aryl or heterocycle.
- R 3 -halogen, lower alkyl, or -0-lower alkyl.
- R 4 a cycloalkyl or a non-aromatic hetero ring, each of which may be substituted, or a lower alkyl substituted with a cycloalkyl.
- R 4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring is bonded to an adjacent ⁇ .
- R 5 - ⁇ , halogen, cyano, nitro, lower alkyl, halogeno lower alkyl, cycloalkyl, aryl, heterocycle, -0-lower alkyl, -OH, -NHCO-lower alkyl, - ⁇ (lower alkyl) CO-amino which may be substituted with lower alkyl, lower alkyl, or cyclic amino which may be substituted.
- R 6 —H, halogen, lower alkyl or halogeno lower alkyl.
- R 7 —H, ⁇ , logen, lower alkyl or halogeno lower alkyl.
- R 2 and R 6 may be combined to form lower alkylene or lower alkylene.
- 7- (hexylamino) -1-ethynole-6-fluoro-1,4-oxo-1,4-dihydroquinoline-3-canolevohydrazide is excluded.
- R 11 is a lower alkyl, each of which is substituted with one or more groups selected from Group Q (at least one is substituted with a group P) (11) Compound. .
- NR “R 12 is a cyclic amino group which is integrally substituted with one or more groups selected from Group Q (at least one is substituted with a group P group) (11) The compound described above.
- the present invention provides a circulating agent closely related to thrombus formation by platelet aggregation, which comprises administering to a patient an effective amount of a quinolone derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention relates to a method for treating an organ disease.
- the active ingredient or the compound of the present invention has a quinolone skeleton in which the ring atom at the 2-position and the Z-position or the 8-position may be substituted with a nitrogen atom and may be condensed by a bond between the 1-position and the 2-position. It has a chemical structural feature in that the 3-position is substituted with aminocarboel and the 3-position is substituted with an amino group. Further, the compound of the present invention has pharmacological characteristics in that it has a platelet aggregation inhibitory action. The present invention will be described in more detail as follows.
- the term “lower” means a straight or branched carbon chain having 1 to 6 carbon atoms unless otherwise specified. ,.,>
- lower alkyl means an alkyl of C 1-6, specifically, for example, methyl, Echiru, propyl, butyl, these structural isomers such as pentyl or hexyl, or Isopuropiru or tert- heptyl And is preferably methyl of 5- alkyl, ethyl, propyl, isopropyl, butyl, isoptyl, and 3-pentyl.
- “Lower alkyl j means a C 2-6 alkyl having one or more double bonds at any position. Specifically, for example, ethenyl, probel, butyr , pentenyl, hexenyl, Butajeniru the like to, preferably Eparu of C 2-3 alkenyl, 1-flop port base - is Honoré, 3 Purobe Yunore '- / Les, 2- Purobe.
- lower alkyl C 2 - means Rukoto that have a one or more triple bonds 6 anywhere in the alkyl.
- “Lower alkylene” means a divalent group obtained by removing one hydrogen at any position of “lower alkyl”, and specifically includes methylene, methylmethylene, ethylene, trimethylene, propylene, butylene and the like. And preferably methylene, ethylene and trimethylene.
- “Lower alkenylene” means a divalent group obtained by removing one hydrogen at any position of “lower alkenyl”, and specifically, vinylene, 1-probellene, 2-pro Penile , 1-butenylene, 2-ptenylene, 3-ptenylene and the like, and preferably vinylene, 1-propenylene and 2-propenylene.
- “Lower alkylidene” means a group in which the free valence formed by removing one hydrogen from a carbon atom having a “lower alkyl” bond becomes part of a double bond.
- Cycloalkyl means a monovalent group of a C 3-8 non-aromatic hydrocarbon ring, which may form a bridged ring or a spiro ring, and has a partially unsaturated bond. May be. Specific examples include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclohexenyl, cyclooctanegenyl, ryodamantyl and norbornyl, etc., and preferably cyclopentyl or cyclopentyl Hexyl. .
- Aryl means a monocyclic to tricyclic C 6-14 aromatic hydrocarbon monovalent group, specifically, for example, phenyl, naphthyl and the like, and preferably phenyl. is there.
- Non-aromatic heterocycle refers to nitrogen, oxygen, sulfur, etc. which may have a partially unsaturated bond, may be condensed with aryl or aromatic heterocycle.
- Heterocycle is a generic term obtained by adding “aromatic heterocycle” to the above “non-aromatic heterocycle”, and “aromatic heterocycle” is selected from the group consisting of nitrogen, oxygen and sulfur.
- a monovalent group of an aromatic hetero ring which may be condensed with a benzene ring, which contains 1 to 4 identical or different hetero atoms, and specifically includes, for example, pyrrolyl, furyl, chenyl, Imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, furazanil, pyridyl, vilanyl, thiopyrael, pyridazinyl, pyrimidinyl, virazil, indolyl, isoindolinole, indolizinole, benzofurinole, benzomizo, benzoimizo, benzoinazo, benzoinazo, benzoimizo ⁇ Benzoxazolyl,
- the nitrogen atom and Z or sulfur atom constituting the ring may be oxidized. Further, these rings may be partially saturated. Preferred are pyridyl, furyl, chenyl, indolyl, indazolyl and benzotriazolyl.
- Halogen means a monovalent group of a halogen atom, and specifically includes, for example, fluoro, chloro, promo, odo, and the like, and is preferably fluoro or chloro.
- Halogeno lower alkyl group means a group in which one or more arbitrary hydrogen atoms of the above “lower alkyl group” are substituted with one or more “halogen”, and specifically, for example, trifluoromethyl, trifluoroethyl And trifluoromethyl. Preferred is trifluoromethyl.
- Cyclic amino is a monovalent heterocyclic group having a bond at the nitrogen atom, and may contain oxygen and sulfur as hetero atoms. Specific examples include pyrrolidino, piperidino, piperazino, homopiperazino, monoreholino, thiomorpholino, 3,4-dihydroisoquinoline-2 (1H) -yl, and the like, preferably pyrrolidino, piperidino, piperazino, 3,4-dihydroiso. It is quinoline-2 (1H) -yl.
- the permissible substituent in the term “optionally substituted” may be any substituent that is commonly used in the art as a substituent of each group. . Further, each group may have one or more same or different substituents.
- Optionally substituted aryl for R 12 , “optionally substituted cyclic amino” for R 11 and R 12 together with adjacent nitrogen atoms; “optionally substituted cycloalkyl” for R 2 alkyl “,” optionally substituted Ariru “,” terrorist ring non-aromatic which may be substituted “,” heterocyclic "to aromatic substituted; be” substituted in 4, R And the optionally substituted non-aromatic heterocycle j; and the optionally substituted cyclic amino in R 5 include the following: (A) The group shown in (h).
- a contact, R z is, -OH, -0- lower alkyl, one or two lower alkyl it may also be substituted I Amino, -C0 2 H, -C0 2 R Z, 1 or 2 Carbamoyl, aryl (which may be substituted with halogen), aromatic heterocyclic substituted with one or more groups selected from the group consisting of aromatic rings and halogens, which may be substituted with two lower alkyls. Represents lower alkyl which may be substituted.
- Aryl or cycloalkyl These groups, -OH, -0- lower alkyl, one or two lower alkyl optionally substituted with Amino, -C0 2 H, -C0 2 R z, one or two lower alkyl May be substituted with one or more groups selected from the group consisting of carpamoyl, aryl, aromatic heterocycle, halogen and Rz .
- (g) An aromatic or non-aromatic hetero ring. These groups, -0H, -0- lower alkyl, Okiso ( 0), one or two lower alkyl optionally substituted with Amino, -C0 2 H, -C0 2 R z, 1 one or two lower alkyl which may be substituted Karupamoiru, Ariru, aromatic heterocycle, with one or more groups selected from the group consisting of halogen ⁇ Pi R z may be each substituted. (h) lower alkyl substituted with one or more groups selected from the substituents shown in (a) to (g) above.
- each of the substituents of the "optionally substituted lower alkyl" or “Moyoi Ariru be substituted” in R 12 or, - NR U R 12 is a case showing a cyclic amino group together
- substituents selected from the following group Q are preferable.
- ⁇ Amino which may be substituted by an optionally substituted lower alkyl group '' means an amino which is mono- or di-substituted by the above-mentioned ⁇ optionally substituted lower alkyl group '', and is a di-substituted amino group.
- Lower alkyl groups may be the same or different from each other.
- X is preferably CH.
- Y is preferably CH or N, and more preferably CH.
- R 11 is preferably -H. ,,,
- R 12 is preferably a lower alkyl or aryl, each preferably substituted with one or more groups selected from the group Q (at least one of which is substituted with a group P); more preferably a group Q Methyl, ethyl, propyl or butyl, each substituted by one or more groups selected from the group consisting of at least one of which is substituted by a group P group.
- the P group and the Q group indicate the following groups.
- -NRUR 12 represents a cyclic amino group in the form of-, it is preferably substituted with one or more groups selected from Group Q (however, at least one is substituted with a group of Group P) A) cyclic amino group.
- R 2 is preferably an optionally substituted lower alkyl, cycloalkyl or non-aromatic heterocycle.
- R 3 is preferably halogen, more preferably fluoro.
- R 4 is preferably a cycloalkyl, and more preferably a cyclohexyl. is there. ⁇
- R 5 is preferably -H, -OH or halogen, more preferably H, -OH or fluoro, and still more preferably -H or -OH.
- R 6 is preferably -H.
- R 7 is preferably -H.
- the quinolone derivative represented by the formula (I) or (I-a) may form a salt, and as long as the salt is a pharmaceutically acceptable salt, the quinolone derivative may be used as the active ingredient of the present invention or the compound of the present invention. Included.
- inorganic salts such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, Acid addition salts with organic acids such as maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, P-toluenesulfonic acid, aspartic acid, glutamic acid, sodium, potassium, calcium, magnesium, etc.
- Inorganic bases including gold leaf, addition salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine, ordithine, and ammonium salts are exemplified.
- the active ingredient or the compound of the present invention may contain an asymmetric carbon atom depending on the type of the substituent, and optical isomers based on this may exist.
- the present invention embraces all mixtures and isolated forms of these optical isomers.
- the active ingredient or the compound of the present invention may have a tautomer, and the present invention includes a separated form or a mixture of these isomers.
- the present invention includes a label body, that is, a compound in which one or more atoms of the active ingredient or the compound of the present invention are substituted with a radioactive isotope or a non-radioactive isotope.
- the present invention also includes various hydrates and solvates of the active ingredient or the compound of the present invention, and substances having crystalline polymorphism.
- the active ingredient or compound f of the present invention is not limited to the compounds described in the following Examples, but may be a derivative represented by the formula (I) or (I-a). It encompasses all pharmaceutically acceptable salts thereof.
- the compound of the present invention includes an active ingredient or a compound of the present invention which is metabolized in a living body. All compounds that are converted into so-called prodrugs are also included. Examples of the group that forms a prodrug of the compound of the present invention include those described in Prog. Med. 5: 2157-2161 (1985), and those described in Hirokawa Shoten 1990, “Development of Pharmaceuticals J, Vol. 7, Molecular Design 163- 198, pages.
- the active ingredient or compound of the present invention can be produced by utilizing various characteristics based on the basic skeleton or the type of the substituent and applying various known synthetic methods. The following is a typical production method.
- it is effective in manufacturing technology to replace the functional group with an appropriate protecting group at the stage of a raw material or an intermediate, that is, a group that can be easily transferred to the functional group. May be important. After removing the protecting group as necessary, the desired compound can be obtained.
- Examples of such a functional group include a hydroxyl group, a hydroxyl group, an amino group and the like, and examples of such a protecting group include "Protective Groups in Organic” by Green and Wuts. Synthesis (third edition) ", and these may be used as appropriate according to the reaction conditions.
- This step is a step of producing a compound (lc) by a condensation-cyclization reaction between the compound (la) and the compound (lb).
- condensation and cyclization reactions in this step can be carried out in the absence of a solvent or in the presence of a high-boiling solvent (difluoroether or the like is preferably used), under heating or under reflux.
- a high-boiling solvent difluoroether or the like is preferably used
- This step is a step of producing a compound (le) by an alkylich reaction between the compound (lc) and the compound (Id).
- the leaving group Lv in the compound (Id) in this step may be any leaving group commonly used in an alkylidation reaction, such as halogen such as bromo, eodo, and chloromethyl, methanesulfonyl / hydroxy, and P-toluene.
- Sulfonyloxy such as sulfonyloxy, trifluoromethanesulfo-loxy and the like are preferably used.
- the method described in j. Med Chem., 23, 1358-1363, 1980, or a method analogous thereto can be used.
- This step is a step of substituting the leaving group of compound (le) with the amino group of compound (If) to produce compound (lg).
- the leaving group Lv in the compound (le) in this step may be any leaving group commonly used in an aromatic nucleophilic substitution reaction, such as halogen such as fluoro, chloromethyl, and promoter; methanesulfonyloxy, p.toluenesulfonyl Sulfonyloxy, such as ethoxy, trifluoromethanesulfonyloxy, etc .; sulfolyl, such as lower alkylsulfol and arylsulfol; are preferably used.
- halogen such as fluoro, chloromethyl, and promoter
- sulfolyl such as lower alkylsulfol and arylsulfol; are preferably used.
- the compound (la) having sulfonyl as Lv can be used as a starting material, and the compound (la) having the corresponding sulfanyl as Lv can be used as a starting material.
- Lv can be converted to sulfonyl by an oxidation reaction using, for example, m-mouth perbenzoic acid and the like, and subjected to the substitution reaction in Step C.
- the substitution reaction in this step is carried out without solvent or with aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as getyl ether, tetrahydrofuran (THF) and dioxane; dichloromethane, 1,2-dichloroethane, and Halogenated hydrocarbons such as form; ⁇ , ⁇ ⁇ ⁇ ⁇ -dimethylformamide (DMF); dimethyl sulfoxide (DMSO); esters such as ethyl acetate (EtOAc); solvents inert to the reaction such as acetonitrile; or methanol (MeOH) In a solvent such as ethanol (EtOH) and 2-propanol, etc., the compound (le) and the compound (If) may be used in an equimolar amount or an excess amount of one, and the reaction can be carried out at room temperature or under reflux with heating.
- aromatic hydrocarbons such as benzene, toluen
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine or the like is preferably used
- a metal salt base carbonated lime, Cesium carbonate, sodium hydroxide, hydration power, Sodium hydride, tert-butoxy potassium, etc. are preferably used) in some cases.
- the compound (lg) is subjected to a hydrolysis reaction to produce the compound (lh).
- the compound (lg) is reacted with aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols, DMF, ⁇ , ⁇ -dimethylacetamide (DMA), N -In a solvent inert to the reaction of methylpyrrolidone, DMSO, pyridine, water, etc., in the presence of mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, and organic acids such as formic acid and acetic acid; or lithium hydroxide
- the reaction can be carried out under cooling or heating to reflux in the presence of a base such as sodium hydroxide, sodium hydroxide, carbon dioxide, sodium carbonate, cesium carbonate or ammonia.
- the reaction temperature can be appropriately selected depending on the compound and the reaction reagent. ,>
- This step is a step of producing the compound (I-b) of the present invention by amidating the compound (li) with the compound h) or a reactive derivative thereof.
- amidation that can be generally used by those skilled in the art can be employed.
- carberdiimidazole GDI
- 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride WSC'HC1
- dicyclohexyl carbodiimide diphenylphosphoryl azide
- getyl Preference is given to a method using a condensing agent such as phosphoryl cyanide, or a method using a mixed acid anhydride using isoptyl chloroformate, ethyl ethyl chloroformate and the like.
- This step is a step of producing compound (lj) by subjecting compound (le) to a hydrolysis reaction, and can be carried out according to step D.
- This step is a step of producing a compound (lh) by substituting the leaving group of the compound (lj) with an amino group of the compound (If), and can be carried out according to the step C.
- This step is a step of producing a compound (lk) by amidating the compound (lj) or a reactive derivative thereof with the compound (li), and can be carried out according to the step E.
- Step J This step is a step of producing a compound (11) by alkylating the compound (la).
- the alkylation in this step can be performed by a method according to Step B or by reductive alkylation.
- the reductive alkylation may employ a reductive alkylation commonly used by those skilled in the art. For example, the method described in “Experimental Chemistry Lecture (4th edition)”, edited by The Chemical Society of Japan, Vol. 20 (1992) (Maruzen) and the like can be mentioned.
- a reducing agent such as sodium hydrogen borohydride or sodium borohydride triacetate in a solvent inert to the reaction of halogenated hydrocarbons, aromatic hydrocarbons, ethers, alcohols, acetic acid, etc.
- reaction it is preferable to carry out the reaction at room temperature or under reflux with heating.
- an acid such as a mineral acid such as sulfuric acid, hydrochloric acid or hydrobromic acid, or an organic acid such as formic acid or acetic acid.
- This step is a step of producing a compound (le) by a condensation-cyclization reaction between the compound (lb) and the compound (11), and can be carried out according to the step A.
- the production method via step A of the present production method is a production method that can be employed even when it is difficult to introduce in step B of the first production method, particularly due to the bulkiness of R 2 such as a tert-butyl group and an adamantyl group. Further, the production method via the step B is a production method that can be adopted also when the and R 6 are in the form of a ring to form a ring.
- This step is a step of producing a compound (2c) by a condensation reaction with the compound (2a) and an orthoformate, followed by an addition-elimination reaction with the compound (2b).
- the condensation reaction with orthoformate in this step can be performed using a reagent that captures alcohols generated from orthoformate such as acetic anhydride as a solvent, or halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF,
- a reagent that captures alcohols generated from orthoformate such as acetic anhydride as a solvent, or halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF
- the reaction can be carried out at room temperature or under reflux with the action of a reagent that captures alcohols generated from orthoformate in a solvent inert to the reaction of esters such as DMSO and ethyl acetate (EtOAc), and acetonitrile. .
- the addition and elimination reaction following the above condensation reaction is carried out in a solvent inert to the reaction of alcohols, halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc., under cooling and at room temperature. It can be carried out under heating to reflux. In addition, the reaction can also be performed using an excessive amount of the compound (2b).
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, etc. is preferably used
- a metal salt base potassium carbonate
- Cesium carbonate sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium, etc. are preferably used) in some cases.
- Step B This step is a step of producing a compound (2c) by an addition-elimination reaction between the compound (2a) and the compound (2d).
- the addition and elimination reaction in this step involves the compound (2a) and the compound (2d) in a solvent inert to the reaction of haegenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc.
- the reaction can be carried out under cooling, at room temperature or under heating to reflux, using an excess amount of one or more moles.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine or the like is preferably used
- a metal salt base carbonic acid rim
- Cesium carbonate, sodium hydroxide, sodium hydroxide, sodium hydride, tert-butoxy potassium, etc. are preferably used) in some cases.
- This step is a step of producing a compound (le) by an intramolecular cyclization reaction of an amino group of the compound (2c).
- the addition-elimination reaction in this step is carried out by cooling compound (2c) in a solvent inert to the reaction such as haegenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc. It can be performed under heating and reflux.
- a solvent inert such as haegenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine or the like is suitably used
- a metal salt base potassium carbonate, cesium carbonate, (Sodium hydroxide, hydroxylated water, sodium hydride, tert-butoxycarbon, etc. are preferably used.) It may be advantageous to carry out in the presence of
- the compound (Ic) of the present invention can be produced by subjecting the compound (le) produced in this step to the same method as in the first production method.
- This production method is a production method that can be employed even when R 2 and R 6 are in a body to form a ring.
- This step is a step of producing a compound (2c) by a condensation reaction between the compound (3a) and the compound (3b).
- a halogen such as chloro, bromo or the like, a sulfonyloxy such as an alkoxy, chlorosiloxy, P-toluenesulfonyl or the like is suitably used.
- a compound (3b,) in which the position of the double bond is isomer can be used instead of the compound (3b) in this step.
- the compound (3a) and the compound (3b) are equimolar to one in a solvent inert to a reaction such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, and DMSO.
- a reaction such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, and DMSO.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, etc.
- the book:! This is a process for producing a compound ae) by a cyclization reaction of the compound (2c).
- the intramolecular cyclization reaction in this step can be performed according to Step C of the second production method.
- step A (le) may be obtained from (3a) without isolating (2c).
- the compound (le) produced in this step may be obtained in the same manner as in the first production method.
- the compound (I-d) of the present invention can be produced by the method.
- This production method is a production method in which a condensed ring is constructed after R 4 NH— is first introduced.
- this step can also be carried out by a substitution reaction using a palladium catalyst (in this case, Lv of compound (la) is preferably halogen such as promoter or eodo, or trifluoromethanesulfonyloxy).
- a palladium catalyst in this case, Lv of compound (la) is preferably halogen such as promoter or eodo, or trifluoromethanesulfonyloxy.
- This step is a step of producing a compound (4b) by a condensation-cyclization reaction between the compound (4a) and the compound (lb), and can be carried out according to the first production step A.
- This step is a step of producing a compound (4c) by an alkylation reaction of the compound (4b) and the compound (Id), and can be carried out according to the first production step B.
- This step is a step of producing compound aw by subjecting compound (4c) to a hydrolysis reaction, and can be carried out according to the first production step D.
- This step is a step of producing the compound (Ie) of the present invention by amidating the compound (lh) or a reactive derivative thereof with the compound (li), and should be carried out according to the first production step E. Can be done.
- This production method is a method for producing a compound in which Y is N in the formula (I) or (Ia).
- This step is a step of diazotizing the compound (5a) and subsequently adding ethyl cyanoacetate to produce the compound (5b).
- the diazotization reaction which is the first step of this process, is carried out in the presence of an acid such as hydrochloric acid, sulfuric acid, or acetic acid, in a solvent inert to water, alcohol, or the like, in a solvent inert to sodium nitrite, ammonium nitrite, or the like.
- the reaction can be carried out under cooling with an equimolar amount of the reagent and the compound (5a) or an excess amount of one of them.
- the addition reaction in the second step can be carried out by cooling the diazo compound produced in the first step and ethyl cyanoacetate using an equimolar amount or an excess amount of one of them in the presence of a base, and at room temperature to heating under reflux.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine or the like is preferably used
- a metal salt base potassium carbonate, Cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium, sodium acetate, etc. are preferably used.
- This step is a step of producing a compound (5c) by an alkyl reaction between the compound (5b) and the compound (Id), and can be carried out according to the first production step B.
- the step is a step of producing the compound (5d) by subjecting the compound (5c) to a hydrolysis reaction, and can be carried out according to the first production process step D.
- compound (5d) is acid-halogenated and cyclized to produce compound (5e).
- the first step of this process is in the absence of a solvent or in the reaction of aromatic hydrocarbons, ethers, halogenated hydrocarbons, esters such as ethyl acetate, acetate and tolyl.
- the compound (5d) and a halogenating agent such as thiol chloride and thioxalyl salt can be used in an equimolar amount or an excess amount of the halogenating agent, and cooled, and the reaction can be carried out at room temperature or under reflux with heating.
- the reaction may advantageously proceed by adding a catalytic amount of DMF or the like.
- the acid halide obtained in the first step can be prepared by using the acid halide obtained in the first step in the presence of Lewis acid such as aluminum chloride, in the absence of a solvent, or by using aromatic hydrocarbons, halogenated hydrocarbons, and ethyl acetate
- the reaction can be carried out in an inert solvent such as an ester or acetonitrile by using an equimolar amount or an excess amount of Lewis acid, cooling, and heating at room temperature to reflux.
- This step is a step of substituting the leaving group of the compound (5e) with the amino group of the compound (If) to produce the compound (5f), which can be carried out according to the first production step C.
- This step is a step of producing the compound (5d) by subjecting the compound (5f) to a hydrolysis reaction, and can be carried out according to the first production step D.
- This step is a step of producing the compound of the present invention (If) by amidating the compound (5g) or a reactive derivative thereof with the compound (li). Can be done. (Sixth manufacturing method)
- This production is a method for producing a compound in which TY is N in formula (I) or (Ia).
- This step is a step of diazotizing compound (2a) to produce compound (6a).
- the diazotization reaction in this step is performed in a solvent inert to a reaction such as hydrocarbons such as pentane and hexane, aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols, acetonitrile, and water.
- the reaction can be carried out at room temperature or under reflux with heating using an equimolar amount or an excess amount of compound (2a) and a diazotizing reagent such as sodium azide and p-toluenesulfol azide.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, etc.
- a metal salt base potassium carbonate
- Cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium tert-butoxide, etc. are preferably used) in some cases.
- a compound (6b) is produced by a reductive intramolecular cyclization reaction of the compound (6a). It is about.
- trialkylphosphine or triarylphosphine can be used as a reducing agent.
- a halogen such as fluoro, black, and promoter
- a sulfooxy such as P-toluenesulfonyl, and nitro are used.
- fluoro the method described in Chem. Pharm. Bull., 36, 1321-1327, 1988, or a method analogous thereto can be used.
- This step is a step of producing a compound (6c) by an alkylation reaction between the compound (6b) and the compound (Id), and can be carried out according to the first production step B.
- This step is a step of producing a compound (6d) by substituting the leaving group of the compound (6c) with an amino group of the compound (If), and can be carried out according to the first production step C.
- This step is a step of producing the compound (6e) by subjecting the compound (6d) to a hydrolysis reaction, and can be carried out according to the first production step D.
- This step is a step of producing the compound (Ig) of the present invention by amidation of the compound (6e) or a reactive derivative thereof and the compound (li), and can be carried out according to the first production step E. it can.
- R 9 and R 1G are H or Represents a lower alkyl group, or R 10 and R 10 may be taken together to represent a lower alkylidene, and m and n represent 0 to 3.
- This production method is a method for producing a compound of formula (I) or (Ia) in which R 2 and R 6 are in a form to form a ring.
- compound (7b) is produced by alkylation reaction of compound (lc,) with compound (7a).
- the alkylic reaction in this step is inert to the reaction of solvents such as aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMSO, esters such as ethyl acetate (EtOAc), and acetonitrile.
- solvents such as aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMSO, esters such as ethyl acetate (EtOAc), and acetonitrile.
- the compound (7c) and the compound (7a) may be used in an appropriate solvent or a solvent such as an alcohol in an equimolar amount or an excess amount of one of them, and the reaction can be carried out at room temperature or under reflux with heating.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, etc.
- a metal salt base potassium, sodium hydroxide,
- the cyclization reaction in this step can be carried out without a solvent or in the presence of a solvent having a high boiling point (1,2-dichlorobenzene or the like is preferably used) and under heating or heating to reflux.
- R 8 forms a leaving group or a triple bond such as a halogen (a port and a promoter are preferably used), a sulfoxy (a methanesulfonyloxy and a p-toluenesulfo-oxyl are preferably used) or the like. If present, this is a step of producing the compound (le,) of the present invention by an intramolecular cyclization reaction of the compound (7c).
- compound (7c) is cooled in a solvent inert to a reaction such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc. without solvent.
- a reaction such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, etc. without solvent.
- the reaction can be carried out at room temperature under reflux with heating.
- an organic base triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (N, N-dimethylamino) pyridine, etc. is preferably used
- a metal salt base carbonate Potassium, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium, etc. are preferably used) in some cases.
- step B (le,) may be obtained from (7b) at once without isolating (7c).
- the compound (Ih) of the present invention can be produced by subjecting the compound (le,) produced in this step to the same method as in the first production method. Further, the compound of formula (I) or (I-a) having a certain power can be obtained from the compound of the present invention obtained as described above by known alkylation, acylation, substitution reaction, oxidation, reduction, hydrolysis, etc. However, it can also be produced by arbitrarily combining steps which can be usually adopted by those skilled in the art. ' ⁇
- the compound of the present invention thus produced can be isolated or purified as it is or by subjecting it to a salt-forming treatment by a conventional method. Isolation and purification are performed by applying ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of mouth chromatography.
- Various isomers can be isolated by a conventional method using a difference in physicochemical properties between the isomers.
- a racemic mixture can be converted to an optically pure isomer by a general racemic resolution method such as a method of leading to a diastereomer salt with a general optically active acid such as tartaric acid and performing optical resolution.
- the diastereo mixture can be separated, for example, by fractional crystallization or various chromatographic methods.
- the optically active compound can also be produced by using a suitable optically active raw material.
- the active ingredient or compound of the present invention has excellent platelet aggregation inhibitory activity and P2Y12 inhibitory activity, and is useful as a medicine, particularly as a platelet aggregation inhibitor and P2Y12 inhibitor. Therefore, the active ingredient or compound of the present invention is closely related to cardiovascular diseases related to thrombus formation due to platelet aggregation, for example, unstable angina, acute myocardial infarction and its secondary prevention, hepatic artery bypass surgery, PTCA Ischemic disease such as reocclusion and restenosis after operative or stent placement, hepatic artery thrombolysis and prevention of reocclusion; transient cerebral ischemic attack (TIA) cerebral infarction, subarachnoid hemorrhage (vascular spasm) It is useful as a prophylactic and / or therapeutic drug for cerebrovascular disorders such as cerebral artery disease and peripheral arterial diseases such as chronic arterial occlusion, and as an adjunct in cardiac surgery or vascular surgery.
- TIA transient cerebral
- PRP platelet-rich plasma
- MAPK-6258 Nihon Kohden
- ADP a platelet aggregation inducer
- MCM Hematotracer 212 M'C Medical
- platelet aggregation was induced by incubating ⁇ 80 ⁇ l with 10 ⁇ l of a solution or solvent (10% DMSO) of the active ingredient or compound of the present invention at 37 ° C. for 1 minute, and then adding 10 ⁇ l of ADP (50 ⁇ ). The change in transmitted light was recorded for 5 minutes. The inhibition rate was calculated using the area under the platelet aggregation curve as an index. Table 1 shows the results at 10 ⁇ M (final concentration) of the active ingredient or compound of the present invention.
- C6-15 cells were seeded in a 10 cm Petri dish using DMEM medium to obtain 1 x 10 s cells and cultured for 1 day. Then, plasmid 8 pEF-BOS-dhfr-human P2Y12 and 0.8 pEF-BOS- neo
- transfected cells were collected, suspended in DMEM medium containing 0.6 mg / ml G418 (GIBCO BRL), and serially diluted to 10 cm Petri dishes. Was reseeded. Colonies that appeared two weeks later were individually obtained and used as P2Y12 protein-expressing C6-15 cells in the following experiments (WO 02/36631, Mol. Pharmacol., 60,432, 2001).
- the cells were collected. After washing the cells with PBS, the cells are suspended in 20 mM Tris-HCl (H7.4) containing 5 mmol / 1 EDTA and Protease Inhibitor Cocktail Set Complete TM (Boehringer-Germanheim), and then subjected to polytron treatment. Homogenized. After ultracentrifugation, the precipitate was suspended in 50 mM Tris-HCl (pH 7.4) containing 1 mM EDTA, 100 mM NaCl and Complete TM, and this was used as a membrane fraction.
- Tris-HCl H7.4
- Protease Inhibitor Cocktail Set Complete TM Boehringer-Germanheim
- a micro scintillator was added to the glass filter, and the radioactivity was measured with a liquid scintillation counter. At the same time, the radioactivity was measured as the total binding amount and the non-specific binding amount of the compound without addition of the compound and the addition of 100 ⁇ M 2-MeS-ADP in 1.5.
- the inhibition rate (%) of the active ingredient or the compound of the present invention was calculated with the total binding amount and the non-specific binding amount being 0% and 100%, respectively.
- Table 2 shows the results for the active ingredient or compound 30 ⁇ (final concentration) of the present invention.
- compositions containing the active ingredient of the present invention can be prepared using tablets, powders, fine granules, granules, capsules, and pills by using carriers, excipients, and other additives that are commonly used for pharmaceuticals. It is prepared into liquids, injections, suppositories, ointments, patches and the like, and is administered orally or parenterally.
- the clinical dose of the active ingredient of the present invention to humans depends on the patient's condition, weight, age and sex. It is appropriately determined in consideration of other factors, but in the case of oral administration, the daily dose is usually about 0.0001 to 50 mg / kg, preferably about 0.001 to 10 mg / kg per body weight, and more preferably. The appropriate dose is 0.01 to 1 mg kg, which should be administered once or in 2 to 4 divided doses. In the case of intravenous administration, the daily dose is about 0.0001 to 1 mg / kg, preferably about 0.0001 to 0.1 mg / kg per body weight, and is administered once or more than once a day. Since the dosage varies under various conditions, a sufficient effect may be obtained with an amount smaller than the above-mentioned dosage range.
- the one or more active substances comprise at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, It is mixed with polyvinylpyrrolidone and magnesium aluminate metasilicate.
- the composition contains additives other than an inert diluent, such as a lubricant such as magnesium stearate, a disintegrant such as calcium cellulose glycolate, a stabilizing agent, a solubilizing agent, etc., according to a conventional method. It may be.
- Tablets or pills may be coated with sugar coating such as sucrose, gelatin, hydroxypropinoresenolerose, hydroxypropylmethinolecellulose phthalate or a gastric or enteric film, if necessary. .
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and commonly used inert diluents such as purified Contains water, ethanol (EtOH).
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as EtOH, polysorbate 80 and the like.
- Such compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing, stabilizing, and dissolving aids. These are sterilized by, for example, filtration through a pateria retaining filter, blending of a bactericide or irradiation. They can also produce sterile solid compositions which can be dissolved in sterile water or sterile injectable solvents before use.
- Rf Reference example number
- Ex Example number (If only the example number is described in the Ex column, it indicates that the compound is a free form, and a diagonal line (/) and HC1 Is shown, indicates that the compound is a hydrochloride.)
- Data Physical data (Sal: salt (no description indicates that the compound is free, for example, if HC1 is described) Indicates that the compound is the hydrochloride salt.))
- R, RR 2 , R 3 , R 4 , A substituents in the general formula (Me: methyl, Et: ethyl ⁇ riPr: normal propyl, iPr: isopropyl, iBu: isobutyl, sBu: sec-butyl, tBu: tert -Butyl, nPen: Normanolepentyl, cPr: Cyclopropyl, cBu: Cyclobutynole, cPen: Cyclopentyl, cHex: Cyclohexyl / cHep: Cycloheptyl, cOct: Cyclooctynole, Ph: Phenyl, Py: Pyridyl, for: furyl, the: cher, Bn: benzyl, btria: benzotriazolyl, bimid: benzimidazolyl, pyrr: pyrrolidyl, pipe: piperid
- the compound of Reference Example 1 was dissolved in toluene, and aniline, cesium carbonate, 2,2, -bis (diphenylphosphino) -1,1, -binaphthyl, and tris (dibenzylideneaceton) dipalladium were added in that order.
- the mixture was stirred at 110 ° C for 2 days to obtain tert-butyl (3-anilino-4-fluorophenyl) rubbamate.
- the compound was dissolved in EtOAc, after adding 4M HCl-EtOAc solution, stirred at room temperature for 1 day, 4 Furuo port - N 3 - was obtained 1,3 Jiamin - phenylalanine benzene.
- the obtained residue was dissolved in 1,4-dioxane, 60% sodium hydride was added at room temperature, the mixture was stirred at 80 ° C for 4 hours, concentrated under reduced pressure, added with aqueous hydrochloric acid, and added with chloroform. Extracted. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated. The obtained residue was dissolved in acetic acid, 6M HCl aq was added at room temperature, and the mixture was stirred at 120 ° C for 5.5 hours, and 1-cyclopentyl-6,7-difluo-4--4-oxo-1,4- Dihydroquinoline-3-carboxylic acid was obtained.
- the compound of Reference Example 5 was suspended in DMF, and potassium carbonate and iodinated thiol were sequentially added under ice-cooling, followed by stirring at room temperature for 4 days, and ethyl 7-anilino-1-ethyl-6-fluoro mouth. -4-oxo-1,4-dihydroquinoline-3-carboxylate was obtained.
- This compound was suspended in 1M NaOH aq, stirred at 100 ° C for 1 hour, and 7-arino-1-ethyl-6-fluoro-1,4-oxo-1,4-dihydroquinoline-3-force The acid was obtained.
- Reference Example 8991 Reference Example 8991 shown in Table 8 was produced using the corresponding raw materials in the same manner as in the method of Reference Example 88.
- Reference Example 8 The compound of No. 8 was dissolved in DMSO, hexylamine was added to the neck, and the mixture was stirred at 80 ° C. for 1 hour, and ethyl 7- (cyclohexylamino) -1-ethyl-5-6-difluo-4-oxo was added.
- -1,4-Dihydro mouth quinoline-3-carboxylate Reference Example 92
- ethyl 5- (cyclohexylamino) -1-ethyl-6,7-difluoro mouth-4-oxo-1,4-dihydroquinoline -3-carboxylate Reference Example 9
- Reference Example 9410 3 shown in Table 9 10 and Reference Example 104 1 106 were produced using the corresponding raw materials.
- Ethyl 3- (2-c-mouth-4,5-difluorophenyl) -3-oxopropanoate was dissolved in acetic anhydride, and ethyl formate was added at room temperature. After stirring for an hour, the mixture was concentrated under reduced pressure. The obtained residue was dissolved in EtOH, and an EtOH solution of triethylamine and tetrahydrofuran-3-amine hydrochloride was added under ice-cooling, and the mixture was stirred under ice-cooling for 30 minutes and at room temperature for 1 hour. Water was added, extracted with ethyl acetate, and dried over anhydrous magnesium sulfate.
- Reference Examples 110 to 125 shown in Table 11 were produced using the corresponding raw materials in the same manner as in Reference Example 109 (however, Reference Examples 12 3 and 12 4 The one in which the hydroxyl group in the corresponding raw material was protected with a tert-butyldimethylsilyl group was used as the raw material.)
- Reference Example 128 was produced using the corresponding raw materials.
- Reference example 1 2 8 2- [7- (Cyclohexylamino) -3- (ethoxycarbonyl) -6-fluoro- 4-oxoquinoline-1 (4H) -yl] propionic acid
- Reference Example 127 The compound of 27 was dissolved in THF, and 1,1, -carbodildimidazole was added under ice-cooling, followed by stirring for 1 hour under ice-cooling. Then, water was added to the reaction mixture, followed by hydrogenation. Boron sodium is added, and the mixture is stirred at room temperature for 4 hours, and ethyl 7- (cyclohexylamino) -6-fluoro-1- (2-hydroxyshethyl) _4-oxo-1,4-dihydroquinoline-3-carboxylate is added. Got.
- Reference Example 130 was produced using the corresponding raw materials in the same manner as Reference Example 129.
- Example 12 The compound of Example 29 was dissolved in salted methylene, pyridinium paratoluenesulfonate and dihydropyran were added in that order under ice cooling, and the mixture was stirred at room temperature for 3 days. Hexylamino) -6-fluoro-4--4-oxo small [2- (tetrahydro-2H-pyran-2-y / reoxy) ethyl] -1,4-dihydroquinoline-3-carboxylate was obtained.
- the compound of Reference Example 1229 was dissolved in dimethylene chloride, and triethylamine and methanesulfonyl chloride were added thereto under ice-cooling, followed by stirring at room temperature for 2 hours to obtain a mesyl compound.
- the mesyl compound was dissolved in DMF, sodium azide was added, and the mixture was stirred at room temperature for 5 hours to obtain an azide compound.
- the azide compound was dissolved in THF, triphenylphenylphosphine was added, the mixture was stirred at 50 ° C for 1 hour, water was added, and the mixture was stirred at 80 ° C with stirring. Pyridine and acetic anhydride are added to the obtained reaction solution, and the mixture is stirred at room temperature for 3 hours.
- Reference Examples 142 to 144 were produced using the corresponding raw materials.
- Reference example 1 4 2 7- (cyclohexylamino) -6-fluoro-1- (1-methylpiperidine-4-yl) -4-oxo-1,4-dihydroquinoline-3-carpoxylate
- REFERENCE EXAMPLE 13 Sodium hydride and methyl iodide were added to a DMF solution of the compound of 37 at 0 ° C, and the mixture was stirred for 5 hours, and ethyl 1- ⁇ 2- [acetyl (methyl) amino] ethyl ⁇ -7- (Six-mouth hexylamino) .6-Funole-4-year-old oxo-1,4-dihydroquinoline-3-carboxylate was obtained.
- Reference Example 149 was produced using the corresponding raw materials.
- Reference Example 151 was produced using the corresponding raw materials.
- Reference Example 153 was produced using the corresponding raw materials.
- Reference example 1 5 4 FAB-MS (Pos); 332 (M + +1)
- Reference Example 15 8-Polyphosphoric acid was added to the compound of Reference Example 15 57, and the mixture was stirred at 130 ° C for 30 minutes, and ethyl 1- (1-ethylpropyl) -5,6,7-trifluoro--4- Oxo-1,4-dihydroquinoline-3-carboxylate was obtained. ⁇
- Reference Example 160 was produced using the corresponding raw materials.
- Reference Example 16 2 was produced using the corresponding raw materials.
- Reference Example 16 The compound of 63 was dissolved in salt dimethylene, trifluoroacetic acid was added, and the mixture was stirred at room temperature for 4 hours to obtain 3-methylcyclopent-3-en-1-amamine trifluoroacetate. Dissolve ethyl 3- (2-chloro-4,5-difluorophenyl) -3-oxopropanoate in acetic anhydride, add ethyl ethyl orthoformate, stir at 150 ° C for 2 hours, and concentrate under reduced pressure did.
- REFERENCE EXAMPLE 16 The compound of 62 was dissolved in EtOH-acetic acid, palladium-carbon (10%) was added, and the mixture was stirred at room temperature for 3 hours in a hydrogen atmosphere, and ethyl 5-aminoethyl-6,7-difluoro- 4-oxo-1,4-dihydroquinoline-3-carpoxylate was obtained.
- LiOH aq was added to a solution of the compound of Reference Example 104 in EtOH-THF, and the mixture was stirred at 60 ° C for 24 hours and at 80 ° C for 24 hours, and then 7- (cyclohexylamino) -1-cyclopentyl-6-fluoromouth-2- Methyl-4-oxo 4,4-dihydroquinoline-3-carboxylic acid was obtained.
- Example 21 The compound of Example 21 was suspended in acetonitrile, and after adding sodium chloride and potassium carbonate, the mixture was stirred at 50 ° C for 7 days, and ethyl 2-cyano [(3,4-difluorophenyl) (ethyl) ) [Drazono] I got an acetate.
- Example 23 The compound of Example 23 was suspended in toluene, and thionyl chloride was added. The mixture was stirred at 90 ° C. for 1.5 hours, and concentrated under reduced pressure. The mixture was azeotropically distilled with toluene, hexane was added to the obtained residue, and the precipitated solid was collected by filtration. The obtained solid was dissolved in dichloroethane, and after adding aluminum chloride, the mixture was stirred at 55 ° C for 24 hours, refluxed for 23 hours, and 1-ethyl-6,7-difluo-4-oxo-1,4. -Dihydrocinnoline-3-carboutryl was obtained.
- Reference Example 25 The compound of 25 was dissolved in acetic acid, HC1 aq was added, and the mixture was stirred at 120 ° C. for 2 days, and the mixture was stirred at 120 ° C. for 2 days. 1,4-Dihydrocinnoline-3-carboxylic acid was obtained.
- Reference Example 230 was produced using the corresponding raw materials.
- Reference Example 13 The compound of Reference Example 130 was dissolved in methylene chloride, and pyridinium paratoluenesulfonate and dihydropyran were added in that order. The mixture was stirred at room temperature overnight, and ethyl 7- (cyclohexylamino) -6- was added. Fluoro-1- [1-methyl-2- (tetrahydro-2H-vilan-2-yloxy) ethyl] -4-oxo_1,4-dihydroquinoline-3-carboxylate was obtained.
- Reference Example 234 was produced using the corresponding raw materials.
- Reference Example 236 was produced using the corresponding raw materials.
- (2-Fluoren-9-ylmethoxy) carbonyl] amino ⁇ ethyl) phosphonic acid is suspended in benzene, benzyl N-dicyclohexylimidocarbamate is added, and the mixture is stirred under reflux conditions for 4 hours. ⁇ [(9H-Fluoren-9-ylmethoxy) carbenole] amino ⁇ ethyl) phosphonate was obtained.
- the compound of Reference Example 237 was dissolved in DMF, and after adding diisopropylethylamine, the mixture was stirred at room temperature for 2 days to obtain dibenzyl (2-aminoethyl) phosphonate. Further, oxalic acid was added to the obtained phosphonate to obtain dibenzyl (2-aminoethyl) phosphonate oxalate.
- Reference Example 241 was produced using the corresponding raw materials.
- Reference Example 59 400 mg of the compound of Example 9 was suspended in 5.0 ml of DMF, and 350 mg of ⁇ , ⁇ -carbonylbis-1 ⁇ -imidazole was added at room temperature, followed by stirring at 100 ° C. for 20 hours. To the resulting reaction solution, 0.2 ml of triethylamine and 180 mg of glycineethyl ester hydrochloride were sequentially added under ice cooling, and the mixture was further stirred at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure, added with water, and extracted with chloroform. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- Example 4 To a solution of 1.106 g of the compound of 4 in 20 ml of black-mouthed form, 2.23 ml of trimethylsilane bromide (TMSBr) was slowly added under ice cooling, and the mixture was stirred for 30 minutes under ice cooling and at room temperature for 6 hours. The reaction solution was concentrated under reduced pressure, and 15 ml of MeOH was added. The mixture was again concentrated under reduced pressure, ether and a small amount of MeOH were added, and the resulting insolubles were collected by filtration. To this was added 10 ml of 1M NaOH aq, MeOH, and water, and the insoluble material was removed by filtration.
- TMSBr trimethylsilane bromide
- Example 374 250 mg of the compound of Example 374 was suspended in 2.0 ml of EtOAc, and 2.0 ml of a 4M HCl-EtOAc solution was added under ice-cooling, followed by stirring at room temperature for 4 days. The precipitated solid was filtered and washed with EtOAc to give ( ⁇ [1-ethyl-6-fluoro-4--4-oxo-7- (piperidine-4-y / reamino) -1, 4-dihydroquinoline-3 -Yl] carboe) amino) acetic acid hydrochloride (210 mg) was obtained.
- Example 16 210 mg of the compound of 1 was suspended in 5.0 ml of DMF, and 0.1 ml of ethoxycarbonylbiperazine, 130 mg of WSCHC1 and 100 mg of 1-hydroxybenzotriazole were added under ice-cooling. After adding mg in order, the mixture was stirred at room temperature for 17 hours. The reaction solution was concentrated under reduced pressure, added with water, and extracted with chloroform. The resulting organic layer with saturated NaHCO 3 aq, washed successively with saturated brine and dried temperament filtered and concentrated under reduced pressure sulfuric anhydride Natoriumu.
- Example 1 9 6 Suspending the compound 530 mg of Example 1 9 6 in a mixed solvent of Aseton 10 ml- water 3.0 ml, N-methylmorpholine at room temperature - N- Okishido 0.30 g, Os0 4 (2.5wt% in tBuOH) 2.0 Then, the mixture was stirred at room temperature for 1 week. Water was added to the reaction solution, 2.0 g of sodium thiosulfate was added at room temperature, and the mixture was stirred at room temperature overnight. The reaction solution was filtered to remove insolubles, and the filtrate was concentrated under reduced pressure.
- Example 7 2 Suspending the compound 423 mg of Example 7 2 to black port Holm 5 ml and MeOH 5 ml, LiOH.H 2 0 126 mg , and the mixture was stirred for 30 minutes at room temperature. To the resulting reaction solution was added 1.17 g of methyl-1-butamate-1-dexoxy-2,3,4-tri-0-acetyl-hi-D-darcopyranoside uronate, and the mixture was stirred at room temperature for 1 hour. Stirred. Further, 126 mg of LiOH.0 and 1.17 g of methyl-1-bromo-1-dexoxy-2,3,4-tri-0-acetyl- ⁇ -D-darcoviranoside uronate were added, followed by stirring at room temperature for 6 hours.
- Example 2 To a suspension of 253 mg of the compound of 10 in 10 ml of THF was added 89 mg of sodium acetate, 55 ⁇ l of formaldehyde solution (37%) and 177 mg of sodium triacetoxyborohydride, and the mixture was stirred at room temperature for 3 hours. . Saturated NaHCO 3 aq was added, and extracted with black port Holm, washed with saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- Example 4 0.45 g of the compound of 12 was dissolved in 10 ml of methylene chloride, and 1.0 ml of trimethylsilane was added under ice-cooling, followed by stirring at room temperature for 3 days. The reaction solution was concentrated under reduced pressure, MeOH was added, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and the solid to be precipitated by adding EtOH was collected by filtration to give [2-( ⁇ [7- (cyclohexylamino) -1-cyclopentyl-6-fluoropent-4-oxo). 344 mg of 1,4-dihydroquinoline-3-yl] carbonyl ⁇ amino) ethyl] phosphonic acid hydrobromide were obtained.
- Example 16 Example 16
- Reference Example 75 The suspension was suspended in 20 ml of the compound of Example 5, and 149 ⁇ l of triethylamine and 117 ⁇ l of isoptyl chloroformate were added thereto under ice-cooling. After stirring for 1 hour as it was, 149 ⁇ l of triethylamine and 138 mg of glycineethyl ester hydrochloride were added, and the mixture was stirred at room temperature for 12 hours. Saturated NH 4 C1 aq was added and extracted with black form. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- Example 200 0.51 g of the compound of Example 200 was dissolved in 5.0 ml of methylene chloride, and 0.5 ml of triethylamine and 0.2 ml of shiridani methanesulfonyl were sequentially added under ice cooling, followed by stirring for 30 minutes under ice cooling. . Water was added to the reaction solution, and the mixture was extracted with chloroform. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a mesyl compound. The obtained mesyl compound was dissolved in 10 ml of DMF, 0.10 g of sodium azide was added under ice cooling, and the mixture was stirred at room temperature for 20 hours.
- Example 5 407 mg of the compound of the 89 compound was dissolved in 5 ml of MeOH, 30 mg of palladium-carbon (10%) was added, and the mixture was stirred under a hydrogen atmosphere for 3 hours. Add 1.15 ml of lMNaOH aq to the reaction solution After adding, insolubles were removed by filtration through Celite.
- Example 31 148 mg of the compound of Example 31 was suspended in 5 ml of acetonitrile, 67 mg of lithium carbonate, 46 ⁇ l of benzyl bromide, and 5 ml of DMF were added, and the mixture was stirred overnight. Water was added, and the mixture was extracted with black hole form and washed with saturated saline. The organic layer is dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure did.
- Example 22 183 mg of the compound of 20 were suspended in 20 ml of chloroform, and 1.35 ml of trimethylsilane bromide was added thereto under ice-cooling, followed by stirring at room temperature for 24 hours. 1.35 ml of trimethylsilane bromide was added, and after stirring for 3 days, EtOH was added. After distilling off the solvent under reduced pressure, water was filtered off the insoluble materials added saturated NaHCO 3 aq. Saturated NaHCO 3 aq was added to this product, and extracted with black port Holm, 1M HCl aq, saturated NaHCO 3 aq, washed with saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the obtained residue was purified by silica gel chromatography, and ethyl [( ⁇ 7- (cyclohexylamino) -6-fluoro-open- 4-oxo-l-[(lRS, 2SR , 3RS, 4SR) -2,3,4-Trihydroxycyclopentyl] -1,4-dihydro p-quinolin-3-yl ⁇ carbonyl) amino] acetate 54 mg.
- Example 15 Compound 743 mg, tetrabutylammonium hydrogensulfate 226 mg, sodium iodide 102 mg, acetonitrile 10 ml, 1,8-diazabicyclo [5.4.0 to 7-indenecene 720 ⁇ .chloropivalate. Add 575 ⁇ of methyl, 75. The mixture was stirred for 65 hours. Water was added, extracted with EtOAc, water, saturated NaHCO 3 aq, washed with saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- Example 5 4 4 273 mg of the compound were suspended in 10 ml of THF, 1.2 ml of 1M LiOH aq was added, and the mixture was stirred at room temperature for 2 days, stirred at 50 ° C for 3 hours, and stirred at 60 ° C for 20 hours. . After evaporating the solvent under reduced pressure, 1M HCl aq was added, and the resulting precipitate was collected by filtration and purified by ( ⁇ [7- (cyclohexylamino) -1- (1-e)
- Example 31 148 mg of the compound of Example 31 was suspended in 5 ml of chloroform, added with 75 ⁇ l of triethyl / reamine, cooled to ⁇ 45 ° C., and added with 32 ⁇ l of methanesulfonyl chloride. After the temperature was gradually raised and the mixture was stirred at room temperature overnight, water was added, and the mixture was extracted with chloroform and washed with saturated saline. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- Example 2 1 0 Compound 1 g saturated NaHCO 3 aq, water, EtOH, and the mixture was extracted with black port Holm. The organic layer is dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to give ethyl ( ⁇ [7- (cyclohexylamino) -6-furoseguchi-4-oxo-1- (pyrrolidine-3-yl)). 750 mg of 1,4-dihydroquinoline-3-yl] potassium ⁇ amino) acetate were obtained.
- Example 2 To 50 mg of the compound of 41, 2 ml of 6M HCl aq was added, and the mixture was stirred at 80 ° C for 1.5 hours. Then, 2 ml of 6M HCl aq was added, and the mixture was stirred at 80 ° C for 1 hour. After evaporating the solvent under reduced pressure, water was added, and the insolubles were collected by filtration. By recrystallization from EtOH, [( ⁇ 7- (hexylhexylamino) -6-fluoro-1- (2-fluoro-1- (fluoromethyl)) ethyl 4-oxo-1,4-dihydroquinoline-3- ⁇ Carbonyl ⁇ amino] acetic acid 18 mg was obtained.
- Example 3 3.
- Example 3 48 mg of the compound of 48 was suspended in 1 ml of DMSO, 46 ⁇ l of triethylamine and 165 ⁇ l of 2.0% dimethylamine in THF were added, and the mixture was stirred at 100 ° C. for 24 hours. A precipitate formed by adding water was collected by filtration. This was dissolved in ethyl acetate and washed with water, saturated N3 ⁇ 4Cl aq, and saturated saline. After drying over anhydrous magnesium sulfate, the mixture was filtered and concentrated under reduced pressure.
- Reference Example 23 Dissolve 53 mg of the compound of 35 in 1.5 ml of DMSO, add 31 ⁇ l of cyclohexylamine at room temperature, and stir at 80 ° C for 13 hours and at 100 ° C for 10 hours. Water was added to the reaction solution, and the generated precipitate was collected by filtration and washed with water. The product was purified by silica gel column chromatography. 51 mg of 1,4-dihydroquinoline-3-yl] carbonyl) amino) acetate were obtained.
- Tables 16 to 41 below show the structures and physical data of the example compounds.
- Tables 45 to 67 show the structures of other compounds of the present invention. These can be easily produced by using the above-mentioned production methods, the methods described in the examples, methods obvious to those skilled in the art, or modifications thereof.
- V3 4-F-cHex cPen (HO) 2 (0) P- (CH 2 ) 2 NH-
- V4 4-F-cHex cPen (HO) 2 (0) P-CF 2 CH 2 NH-
- V5 4-F-cHex (Et) 2 CH- H0 2 C-CH 2 NH-
- V6 4-F-cHex (Et) 2 CH- (S) -H0 2 C- (CH 2 ) 2CH (C0 2 H) NH-
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04748045A EP1650192A4 (en) | 2003-07-24 | 2004-07-22 | QUINOLONE DERIVATIVE OR SALT THEREOF |
US10/562,128 US7488739B2 (en) | 2003-07-24 | 2004-07-22 | Quinolone derivative or salt thereof |
CA002530352A CA2530352A1 (en) | 2003-07-24 | 2004-07-22 | Quinolone derivative or salt thereof |
MXPA06000675A MXPA06000675A (es) | 2003-07-24 | 2004-07-22 | Derivado de quinolona o sal del mismo. |
US12/347,428 US7879878B2 (en) | 2003-07-24 | 2008-12-31 | Quinolone derivative or salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-278852 | 2003-07-24 | ||
JP2003278852 | 2003-07-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10562128 A-371-Of-International | 2004-07-22 | ||
US12/347,428 Continuation US7879878B2 (en) | 2003-07-24 | 2008-12-31 | Quinolone derivative or salt thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005009971A1 true WO2005009971A1 (ja) | 2005-02-03 |
Family
ID=34100788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010781 WO2005009971A1 (ja) | 2003-07-24 | 2004-07-22 | キノロン誘導体又はその塩 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7488739B2 (ja) |
EP (1) | EP1650192A4 (ja) |
KR (1) | KR20060041254A (ja) |
CN (1) | CN100471842C (ja) |
CA (1) | CA2530352A1 (ja) |
MX (1) | MXPA06000675A (ja) |
WO (1) | WO2005009971A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006077851A1 (ja) * | 2005-01-20 | 2006-07-27 | Astellas Pharma Inc. | キノロン誘導体又はその塩 |
WO2007105751A1 (ja) | 2006-03-16 | 2007-09-20 | Astellas Pharma Inc. | キノロン誘導体又はその製薬学的に許容される塩 |
WO2008062770A1 (fr) * | 2006-11-22 | 2008-05-29 | Astellas Pharma Inc. | Dérivé de quinolone ou sel acceptable du point de vue pharmaceutique de celui-ci |
WO2008131134A1 (en) * | 2007-04-17 | 2008-10-30 | Cylene Pharmaceuticals, Inc. | Hydrazide compounds and uses thereof |
WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
US7910576B2 (en) | 2007-06-18 | 2011-03-22 | Sanofi-Aventis | Pyrrole derivatives as P2Y12 antagonists |
US8168658B2 (en) | 2006-02-28 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
AU2007225088B2 (en) * | 2006-03-13 | 2012-09-13 | Kyorin Pharmaceutical Co., Ltd | Aminoquinolones as GSK-3 inhibitors |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8461189B2 (en) | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
WO2014003098A1 (ja) * | 2012-06-28 | 2014-01-03 | 第一三共株式会社 | 三環性化合物 |
US8669266B2 (en) | 2007-04-23 | 2014-03-11 | Sanofi | Quinoline-carboxamide derivatives as P2Y12 antagonists |
WO2016198342A1 (de) * | 2015-06-09 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
JP2017538689A (ja) * | 2014-11-17 | 2017-12-28 | ニーロジョン セラピューティクス インコーポレイテッドNirogyone Therapeutics, Inc. | モノカルボン酸輸送修飾薬およびその使用 |
WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018050510A1 (de) | 2016-09-14 | 2018-03-22 | Bayer Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US7488739B2 (en) * | 2003-07-24 | 2009-02-10 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
DE602006015851D1 (de) * | 2005-12-05 | 2010-09-09 | Merck Sharp & Dohme | Positive allosterische chinolon-m1-rezeptormodulatoren |
AU2006331614A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2699151A1 (en) | 2007-09-11 | 2009-03-19 | Activx Biosciences, Inc. | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
CA2699152C (en) | 2007-09-12 | 2015-11-24 | Activx Biosciences, Inc. | Spirocyclic aminoquinolones as gsk-3 inhibitors |
RU2483072C2 (ru) * | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
MX2011009414A (es) | 2009-03-11 | 2011-10-19 | Kyorin Seiyaku Kk | 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3. |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
US8134020B2 (en) * | 2009-12-10 | 2012-03-13 | The United States Of America As Represented By The Secretary Of The Army | Polymerization of hydroxytyrosol mediated by horseradish peroxidases |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
WO2012174013A2 (en) * | 2011-06-14 | 2012-12-20 | Cardeus Pharmaceuticals, Inc. | Treatment of cardiovascular disease, stroke, and inflammatory conditions |
EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
GB202015056D0 (en) | 2020-09-23 | 2020-11-04 | Cambridge Entpr Ltd | Biomarkers |
WO2022195525A1 (en) * | 2021-03-19 | 2022-09-22 | Zydus Lifesciences Limited | A quinolone compound in solid forms and processes for the preparation thereof |
CN113461612B (zh) * | 2021-07-20 | 2022-10-14 | 上海应用技术大学 | 一种喹诺酮类端锚聚合酶2抑制剂及其制备方法和应用 |
WO2023170724A1 (en) * | 2022-03-08 | 2023-09-14 | The University Of Jordan | Use of substituted quinolone derivatives for treating cancer |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5029574A (ja) * | 1973-02-26 | 1975-03-25 | ||
JPS5035191A (ja) * | 1973-04-05 | 1975-04-03 | ||
WO1998023592A1 (fr) * | 1996-11-28 | 1998-06-04 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif |
JP2001139555A (ja) * | 1999-11-10 | 2001-05-22 | Pfizer Prod Inc | 7−[(4’−トリフルオロメチル−ビフェニル−2−カルボニル)アミノ]−キノリン−3−カルボン酸アミド、及びアポリポタンパク質bの分泌阻害方法 |
WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
GB2372986A (en) * | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
JP2002531567A (ja) * | 1998-12-04 | 2002-09-24 | アストラゼネカ アクチボラグ | 新規なトリアゾロ(4,5−d)ピリミジン化合物 |
WO2002092571A1 (en) * | 2001-05-11 | 2002-11-21 | Astrazeneca Ab | Novel 4-anilinoquinoline-3-carboxamides |
WO2002098856A2 (en) * | 2001-06-06 | 2002-12-12 | Schering Aktiengesellschaft | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
WO2003022214A2 (en) * | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
WO2004019932A1 (en) * | 2002-08-30 | 2004-03-11 | Pharmacia & Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024255A (en) | 1973-04-05 | 1977-05-17 | Allen & Hanburys Limited | Tetrazole containing naphthyridine-3-carboxamides |
US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
EP0673247A4 (en) | 1992-12-01 | 1996-05-01 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
TW301607B (ja) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
WO1997004779A1 (en) | 1995-08-02 | 1997-02-13 | Chiroscience Limited | Quinolones and their therapeutic use |
CA2225555A1 (en) | 1995-08-02 | 1997-02-13 | Chiroscience Limited | Quinolones and their therapeutic use |
DE69736812T2 (de) * | 1996-11-27 | 2007-08-09 | Bristol-Myers Squibb Pharma Co. | Neue integrin rezeptor antagonisten |
CN1128790C (zh) | 1997-12-22 | 2003-11-26 | 法玛西雅厄普约翰美国公司 | 用作抗病毒剂的4-羟基喹啉-3-甲酰胺和酰肼化合物 |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
TW500724B (en) | 1999-10-05 | 2002-09-01 | Pharmacia & Amp Upjohn Company | Oxazinoquinolones useful for the treatment of viral infections |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
CA2399741A1 (en) | 2000-03-21 | 2001-11-01 | Scott D. Larsen | 4-hydroxycinnoline-3-carboxyamides as antiviral agents |
US6682892B2 (en) | 2000-07-13 | 2004-01-27 | Pharmacia & Upjohn Company | Method for treating herpes viruses |
WO2002070487A1 (en) | 2001-03-01 | 2002-09-12 | Pharmacia & Upjohn Company | Substituted quinolinecarboxamides as antiviral agents |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7488739B2 (en) * | 2003-07-24 | 2009-02-10 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
-
2004
- 2004-07-22 US US10/562,128 patent/US7488739B2/en not_active Expired - Fee Related
- 2004-07-22 KR KR1020067001356A patent/KR20060041254A/ko active IP Right Grant
- 2004-07-22 CN CNB2004800211878A patent/CN100471842C/zh not_active Expired - Fee Related
- 2004-07-22 EP EP04748045A patent/EP1650192A4/en not_active Withdrawn
- 2004-07-22 CA CA002530352A patent/CA2530352A1/en not_active Abandoned
- 2004-07-22 WO PCT/JP2004/010781 patent/WO2005009971A1/ja not_active Application Discontinuation
- 2004-07-22 MX MXPA06000675A patent/MXPA06000675A/es active IP Right Grant
-
2008
- 2008-12-31 US US12/347,428 patent/US7879878B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5029574A (ja) * | 1973-02-26 | 1975-03-25 | ||
JPS5035191A (ja) * | 1973-04-05 | 1975-04-03 | ||
WO1998023592A1 (fr) * | 1996-11-28 | 1998-06-04 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif |
JP2002531567A (ja) * | 1998-12-04 | 2002-09-24 | アストラゼネカ アクチボラグ | 新規なトリアゾロ(4,5−d)ピリミジン化合物 |
JP2001139555A (ja) * | 1999-11-10 | 2001-05-22 | Pfizer Prod Inc | 7−[(4’−トリフルオロメチル−ビフェニル−2−カルボニル)アミノ]−キノリン−3−カルボン酸アミド、及びアポリポタンパク質bの分泌阻害方法 |
WO2001057037A1 (en) * | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
GB2372986A (en) * | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
WO2002092571A1 (en) * | 2001-05-11 | 2002-11-21 | Astrazeneca Ab | Novel 4-anilinoquinoline-3-carboxamides |
WO2002098856A2 (en) * | 2001-06-06 | 2002-12-12 | Schering Aktiengesellschaft | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
WO2003022214A2 (en) * | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
WO2004019932A1 (en) * | 2002-08-30 | 2004-03-11 | Pharmacia & Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
Non-Patent Citations (4)
Title |
---|
DATABASE CHEMCATS [online] 2002, XP002982454, accession no. STN Database accession no. 2002:2172297 * |
DATABASE CHEMCATS [online] 2002, XP002982455, accession no. STN Database accession no. 2002:163154 * |
DATABASE CHEMCATS [online] 2003, XP002982453, accession no. STN Database accession no. 2003:2205826 * |
See also references of EP1650192A4 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006077851A1 (ja) * | 2005-01-20 | 2006-07-27 | Astellas Pharma Inc. | キノロン誘導体又はその塩 |
US8168658B2 (en) | 2006-02-28 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
AU2007225088B2 (en) * | 2006-03-13 | 2012-09-13 | Kyorin Pharmaceutical Co., Ltd | Aminoquinolones as GSK-3 inhibitors |
EP1995240A4 (en) * | 2006-03-16 | 2009-12-09 | Astellas Pharma Inc | CHINOLO DERIVATIVES BZW. PHARMACEUTICALLY ALLOWED SALT FROM THIS |
EP1995240A1 (en) * | 2006-03-16 | 2008-11-26 | Astellas Pharma Inc. | Quinolone derivative or pharmaceutically acceptable salt thereof |
US8629126B2 (en) | 2006-03-16 | 2014-01-14 | Astellas Pharma Inc. | Quinolone derivative or pharmaceutically acceptable salt thereof |
US8133882B2 (en) | 2006-03-16 | 2012-03-13 | Astellas Pharma Inc | Quinolone derivative or pharmaceutically acceptable salt thereof |
CN101400655B (zh) * | 2006-03-16 | 2013-01-09 | 安斯泰来制药有限公司 | 喹诺酮衍生物或其制药学可接受的盐 |
WO2007105751A1 (ja) | 2006-03-16 | 2007-09-20 | Astellas Pharma Inc. | キノロン誘導体又はその製薬学的に許容される塩 |
WO2008062770A1 (fr) * | 2006-11-22 | 2008-05-29 | Astellas Pharma Inc. | Dérivé de quinolone ou sel acceptable du point de vue pharmaceutique de celui-ci |
WO2008131134A1 (en) * | 2007-04-17 | 2008-10-30 | Cylene Pharmaceuticals, Inc. | Hydrazide compounds and uses thereof |
WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
US8669266B2 (en) | 2007-04-23 | 2014-03-11 | Sanofi | Quinoline-carboxamide derivatives as P2Y12 antagonists |
US7910576B2 (en) | 2007-06-18 | 2011-03-22 | Sanofi-Aventis | Pyrrole derivatives as P2Y12 antagonists |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8461189B2 (en) | 2007-06-27 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyridyl derivatives as histone deacetylase inhibitors |
US9096559B2 (en) | 2007-06-27 | 2015-08-04 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2014003098A1 (ja) * | 2012-06-28 | 2014-01-03 | 第一三共株式会社 | 三環性化合物 |
JP2017538689A (ja) * | 2014-11-17 | 2017-12-28 | ニーロジョン セラピューティクス インコーポレイテッドNirogyone Therapeutics, Inc. | モノカルボン酸輸送修飾薬およびその使用 |
WO2016198342A1 (de) * | 2015-06-09 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | Positiv allosterische modulatoren des muskarinergen m2 rezeptors |
US10435403B2 (en) | 2015-06-09 | 2019-10-08 | Bayer Pharma Aktiengesellschaft | Positive allosteric modulators of muscarinic M2 receptor |
WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
US10519154B2 (en) | 2016-07-11 | 2019-12-31 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
WO2018050510A1 (de) | 2016-09-14 | 2018-03-22 | Bayer Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
US10927109B2 (en) | 2016-09-14 | 2021-02-23 | Bayer Aktiengesellschaft | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof |
US11472803B2 (en) | 2016-09-14 | 2022-10-18 | Bayer Aktiengesellschaft | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1826321A (zh) | 2006-08-30 |
MXPA06000675A (es) | 2006-04-19 |
US7879878B2 (en) | 2011-02-01 |
CN100471842C (zh) | 2009-03-25 |
KR20060041254A (ko) | 2006-05-11 |
CA2530352A1 (en) | 2005-02-03 |
US20090124617A1 (en) | 2009-05-14 |
US20060148806A1 (en) | 2006-07-06 |
US7488739B2 (en) | 2009-02-10 |
EP1650192A1 (en) | 2006-04-26 |
EP1650192A4 (en) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005009971A1 (ja) | キノロン誘導体又はその塩 | |
AU2013296627C9 (en) | Deuterated ibrutinib | |
CA2743902C (en) | Substituted dioxopiperidinyl phthalimide derivatives | |
JP2019059783A (ja) | 1,4−二置換ピリダジン誘導体およびsmn欠損に関連する状態を処置するためのその使用 | |
WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
WO2007105751A1 (ja) | キノロン誘導体又はその製薬学的に許容される塩 | |
JP2018511626A (ja) | ブロモドメイン阻害剤 | |
TW200529846A (en) | 3-quinolinecarbonitrile protein kinase inhibitors | |
NZ538617A (en) | Azaarene derivatives | |
WO2001083456A1 (fr) | Derives d'heteroaryle condenses | |
JP5856086B2 (ja) | 薬物製造のためのイソキノロン類の使用、新規なイソキノロン類およびそれらの合成方法 | |
WO2014040549A1 (zh) | 炔杂芳环化合物及其应用 | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
WO2014180182A1 (zh) | [1,2,4]三唑并[4,3-a]吡啶类衍生物,其制备方法或其在医药上的应用 | |
EP3768666A1 (en) | Compounds and methods for ido and tdo modulation, and indications therefor | |
JP2001048786A (ja) | 三環式ヘテロアリール誘導体 | |
CA3093138C (en) | Heteroaryl compounds as kinase inhibitor | |
JP2014526524A (ja) | キナーゼ阻害剤としてのピリジン化合物 | |
JP4853824B2 (ja) | キノロン誘導体を有効成分とする医薬組成物 | |
TW200829568A (en) | Quinolone derivative or pharmaceutically acceptable salt thereof | |
JP4858683B2 (ja) | キノロン誘導体又はその塩の製造法 | |
JP6526060B2 (ja) | 置換トリアゾロベンゾジアゼピン | |
JP4725047B2 (ja) | キノロン誘導体又はその塩 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
CN111108083B (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480021187.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2530352 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006148806 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10562128 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 144/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/000675 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004748045 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067001356 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004748045 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10562128 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |